BTICs are usually refractory to conventional anti-cancer drugs through their capacity for increased DNA repair, overexpression of ABC-transporters, high ALDH1 activity and inhibition of apoptosis pathways [22]. This evidence concerns the gene ALDH1A1 and cancer.